Lista de obras - Michael B Boffa - Dominio Público Uruguay

A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels

scientific article published on 01 September 2001

A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor

artículo científico publicado en 2002

A role for apolipoprotein(a) in protection of the low-density lipoprotein component of lipoprotein(a) from copper-mediated oxidation

artículo científico publicado en 2003

A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor

artículo científico publicado en 1998

Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.

artículo científico publicado en 2016

Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.

artículo científico publicado en 2017

Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells

artículo científico publicado en 2003

Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system

artículo científico publicado en 2013

Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation

artículo científico publicado en 2008

Apolipoprotein(a) stimulates nuclear translocation of β-catenin: a novel pathogenic mechanism for lipoprotein(a).

artículo científico publicado en 2012

Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10.

artículo científico publicado en 2005

Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

artículo científico publicado en 2013

Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis

artículo científico publicado en 2007

Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease

artículo científico publicado en 2016

Functional analysis of mutant variants of thrombin-activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin

artículo científico publicado en 2009

Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin

artículo científico publicado en 2016

Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells

scientific article published on 20 April 2011

Identification of tristetraprolin as a factor that modulates the stability of the TAFI transcript through binding to the 3'-untranslated region

artículo científico publicado en 2012

Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).

artículo científico

Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces

artículo científico publicado en 2003

Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency

artículo científico publicado en 2016

Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

artículo científico publicado en 2015

Lipoprotein(a) as a therapeutic target in cardiovascular disease

artículo científico

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor

artículo científico publicado en 2015

Lipoprotein(a): a unique risk factor for cardiovascular disease.

artículo científico publicado en 2006

Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum.

artículo científico publicado en 2014

Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).

artículo científico publicado en 2015

Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter

artículo científico publicado en 2007

Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties

artículo científico publicado en 1998

Pro-inflammatory cytokines reduce human TAFI expression via tristetraprolin-mediated mRNA destabilisation and decreased binding of HuR

artículo científico publicado en 2015

Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone.

artículo científico publicado en 2013

Regulation of the mouse gene encoding TAFI by TNFα: role of NFκB binding site

artículo científico publicado en 2012

Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor

artículo científico publicado en 2004

Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor

artículo científico publicado en 2000

Screening for and management of elevated Lp(a).

artículo científico publicado en 2013

Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets

artículo científico publicado en 2010

Simultaneous R2* and quantitative susceptibility mapping measurement enables differentiation of thrombus hematocrit and age: an in vitro study at 3 T

scientific article published on 14 May 2019

Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9

scientific article published on 21 October 2004

Subclinical vitamin K deficiency in hemodialysis patients

artículo científico publicado en 2007

TAFI and wound healing: closing a knowledge gap

artículo científico publicado en 2003

The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells

artículo científico publicado en 2003

The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity

artículo científico publicado en 2013

The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface

artículo científico publicado en 1997

Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.

artículo científico publicado en 2001

Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

artículo científico

Lista de obras de Michael B Boffa

A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels

A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor

A role for apolipoprotein(a) in protection of the low-density lipoprotein component of lipoprotein(a) from copper-mediated oxidation

A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor

Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.

Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.

Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells

Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system

Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation

Apolipoprotein(a) stimulates nuclear translocation of β-catenin: a novel pathogenic mechanism for lipoprotein(a).

Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10.

Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis

Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease

Functional analysis of mutant variants of thrombin-activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin

Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin

Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells

Identification of tristetraprolin as a factor that modulates the stability of the TAFI transcript through binding to the 3'-untranslated region

Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).

Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces

Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency

Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Lipoprotein(a) as a therapeutic target in cardiovascular disease

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor

Lipoprotein(a): a unique risk factor for cardiovascular disease.

Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum.

Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).

Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter

Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties

Pro-inflammatory cytokines reduce human TAFI expression via tristetraprolin-mediated mRNA destabilisation and decreased binding of HuR

Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone.

Regulation of the mouse gene encoding TAFI by TNFα: role of NFκB binding site

Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor

Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor

Screening for and management of elevated Lp(a).

Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets

Simultaneous R2* and quantitative susceptibility mapping measurement enables differentiation of thrombus hematocrit and age: an in vitro study at 3 T

Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9

Subclinical vitamin K deficiency in hemodialysis patients

TAFI and wound healing: closing a knowledge gap

The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells

The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity

The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface

Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.

Update on lipoprotein(a) as a cardiovascular risk factor and mediator.